AB0635 POTENTIAL BIOMARKERS OF SKIN CHANGES IN SYSTEMIC SCLEROSIS

Background: Skin fibrosis is a hallmark of systemic sclerosis (SSc). There are no widely accepted biomarkers of skin involvement in this condition. Several serum or plasma markers have been studied in patients with SSc - monocyte chemoattractant protein-1 (MCP-1), chemokine (C-X-C motif) ligand 8 (CXCL8), interleukin-13 (IL-13), and some more recognized such as - platelet derived growth factor (PDGF), transforming growth factor-beta 1 (TGF-beta 1), epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF). Objectives: The aim of this study was to assess several circulating biomarkers which may be relevant to the fibrosing process and further to correlate the obtained data with clinical indicators specific for SSc skin involvement. Methods: 59 SSc patients (M/F 9/50; mean age 52.1 years, mean disease duration 6.7 years, 36 patients with limited cutaneous SSc and 23 with diffuse cutaneous SSc. As a control group 36 healthy individuals matched to sex and age were examined. Serum concentrations of bFGF, granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage-colony stimulating factor (GM-CSF), MCP-1, PDGF, IL-8 and 13 were analysed using commercial multiplex kit. The following clinical examinations were performed: modified Rodnan skin score (mRSS), Hand Mobility in Scleroderma Test (assessing hand function) (HAMIS), Cochin Hand Function Scale (hand function) (CHFS), Delta Finger-to-Palm Distance (extension-flexion) (dFTP), inter-lip Distance (inter-lip), inter-incisor Distance (inter-incisor), and Mouth Handicap in Systemic Sclerosis Scale (mouth opening) (MHISS). For statistical evaluation Spearman’s correlation coefficient was used. Results: When compared with healthy controls serum concentrations of bFGF (p Conclusion: Our results have shown that G-CSF, GM-CSF and IL-8 play a substantial role in SSc fibrosing process. Potential biomarkers as bFGF, G-CSF, MCP-1 and IL-8 correlated with a few clinical indices of SSc skin involvement. References [1] Carulli MT, Handler C, Coghlan JG, Black CM, Denton CP. Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?Ann Rheum Dis2008;67:105-9. [2] Chujo S, Shirasaki F, Kondo-Miyazaki M, Ikawa Y, Takehara K. Role of connective tissue growth factor and its interaction with basic fibroblast growth factor and macrophage chemoattractant protein-1 in skin fibrosis. J Cell Physiol2009;220:189-95. [3] Fuschiotti P, Larregina aT, Ho J, Feghali-Bostwick C, Medsger TA Jr. Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis. Arthritis Rheum2013;65:236-46. [4] Hasegawa M, Fujimoto M, Matsushita T, et al. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol2011;30:231-7. Acknowledgement: This study was supported by research grants aZV 16-33574A and aZV 16-33542A. Disclosure of interests: Radim Becvař Consultant for: consultancy actelion, Hana Storkanova: None declared, Barbora Sumova: None declared, Maja Spiritovic: None declared, Sabina Oreska: None declared, Ladislav Senolt Grant/research support from: abbVie, Consultant for: abbVie, Bristol-Myers Squibb, Celgene Corporation, Merck Sharp and Dohme, Novartis, Pfizer, Roche, UCB, amgen, Takeda, Speakers bureau: abbVie, amgen, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly, Merck Sharp and Dohme, Novartis, Pfizer, Roche, UCB, Michal Tomcik: None declared